New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 24, 2014
06:35 EDTLLYEli Lilly still sees FY14 adjusted EPS $2.72-$2.80, consensus $2.81
Now sees FY14 reported EPS $2.70-$2.78. Sees FY14 revenue $19.4B-$20B, consensus $19.75B. . As described in the company's initial guidance, patent expirations are expected to drive a rapid and severe decline in U.S. Cymbalta and U.S. Evista sales. These revenue declines are expected to be partially offset by growth from a portfolio of other products including Humalog, Trajenta®, Cialis, Forteo and Alimta, as well as the animal health business. In addition, strong revenue growth is expected in China, while a weaker Japanese yen will dampen revenue growth in Japan.The company now anticipates that gross margin as a percent of revenue will be approximately 73% in 2014. Total operating expenses in 2014 are expected to decrease substantially compared to 2013. The 2014 tax rate is now expected to be approximately 19%, assuming a full-year 2014 benefit of the R&D tax credit and other tax provisions up for extension. If these items are not extended, the 2014 tax rate would be approximately 2 percentage points higher. The company now expects 2014 net income to be at least $2.9B and still expects operating cash flow to be at least $4B. Operating cash flows are still expected to be sufficient to pay the company's dividend of approximately $2.1B, allow for capital expenditures of approximately $1.3B, and fund certain business development activity and share repurchases. The company's 2014 financial guidance assumes that the acquisition of Novartis Animal Health does not close during this calendar year. Should the acquisition close during 2014, the company will revise its 2014 financial guidance, if necessary.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
11:09 EDTLLYFTC puts conditions on Lilly's proposed acquisition of Novartis Animal Health
Global pharmaceutical company Eli Lilly and Company (LLY) has agreed to divest its Sentinel product line of medications for treating heartworm disease in dogs in order to settle FTC charges that its proposed $5.4B acquisition of Novartis (NVS) Animal Health would likely be anticompetitive. Under the proposed settlement, Eli Lilly will divest its Sentinel product line and associated assets to the French pharmaceutical company, Virbac. Indianapolis-based Eli Lilly, through its Elanco Animal Health division, and Switzerland-based Novartis AG’s Novartis Animal Health business unit both develop and market a wide range of animal health products, including medications to treat diseases and conditions affecting pets and livestock. Reference Link
10:02 EDTLLYEli Lilly announces diabetes research partnership with University of Surrey
Subscribe for More Information
07:56 EDTLLYEli Lilly price target raised to $76 from $67 at Leerink
Subscribe for More Information
December 19, 2014
09:48 EDTLLYBiogen should be bought on weakness after Roche drug halted, says Evercore ISI
Subscribe for More Information
08:53 EDTLLYBiogen drug, trial differs from Roche Alzheimer's drug, says RBC Capital
Subscribe for More Information
05:39 EDTLLYEli Lilly, Adocia to co-develop BioChaperone Lispro
Subscribe for More Information
December 16, 2014
14:48 EDTLLYEli Lilly's CYRAMZA receives third FDA approval
Subscribe for More Information
December 15, 2014
16:33 EDTLLYEli Lilly raises quarterly dividend 2% to 50c per share
Subscribe for More Information
December 12, 2014
12:52 EDTLLYEli Lilly: FDA expands approved use of Cyramza to treat lung cancer
Subscribe for More Information
December 11, 2014
10:13 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:40 EDTLLYEli Lilly upgraded at Morgan Stanley
As previously reported, Morgan Stanley upgraded Eli Lilly two notches to Overweight from Underweight. The firm has increased confidence in Eli Lilly's pipeline investments following recent external data in Alzheimer's and atherosclerosis and now expects potential evacetrapib peak sales of $3B and solanezumab peak sales of $10B. Price target raised to $85 from $60.
06:22 EDTLLYEli Lilly upgraded to Overweight from Underweight at Morgan Stanley
Subscribe for More Information
December 9, 2014
07:44 EDTLLYAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
07:11 EDTLLYEli Lilly and Incyte announce Phase 3 RA-BEACON study met primary endpoint
Subscribe for More Information
December 8, 2014
08:10 EDTLLYLilly, Anthem, HealthCore form five-year research collaboration
Eli Lilly and Company (LLY), Anthem (ANTM) and HealthCore, Inc. announced that they have formed a five-year, real-world evidence research collaboration intended to improve health outcomes for patients. The companies will jointly develop and conduct research projects in health outcomes and real-world evidence in areas of mutual interest. Each party will bring distinct and valuable contributions to the collaboration, including the U.S. provider and patient environment, research capabilities, therapeutics and methods expertise, and integrated, researchable data. The collaboration allows the organizations to explore research opportunities across disease states and incorporate surveys and other information from providers and patients.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use